CELEBRATION

Zevra Therapeutics to Participate at Upcoming Investor Events

Retrieved on: 
Thursday, May 9, 2024
Conference, Disease, The Citizen, Therapy

CELEBRATION, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will present at several upcoming investor events in May 2024.

Key Points: 
  • CELEBRATION, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will present at several upcoming investor events in May 2024.
  • Additionally, management will be available for one-on-one meetings with registered attendees.
  • Mr. McFarlane will present at The Citizens JMP Life Sciences Conference in New York, NY, on Tuesday, May 14, at 1 p.m.
  • Mr. McFarlane and members of the Zevra management team will also attend and be available for one-on-one meetings at the Mizuho Neurosciences Summit in Boston, MA, on May 21.

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

Retrieved on: 
Wednesday, May 8, 2024
Corporation, FDA, Society, EAP, Sale, Celiprolol, Acer, Investment, Priority review, NDA, Conference call, Research, Sleep, License, Conference, Discover, Idiopathic hypersomnia, Disease, Exercise, IH, PDUFA, Patient, Acquisition, Physician, NPC, UCD, Caregiver, Therapy, Pharmaceutical industry

CELEBRATION, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the first quarter ended March 31, 2024. 

Key Points: 
  • ET
    CELEBRATION, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the first quarter ended March 31, 2024.
  • Zevra has seen a meaningful increase in reimbursement coverage, reaching nearly 75% of covered lives as of May 1, 2024.
  • Overview of Q1 2024 Financial Results:
    Net revenue for Q1 2024 was $3.4 million, compared to net revenue of $3.2 million in Q1 2023.
  • ET, to discuss its corporate and financial results for Q1 2024.

La Rosa Acquires Tenth Real Estate Brokerage Franchisee with Revenue of $4.7 Million and Positive Net Income in 2023

Retrieved on: 
Thursday, April 25, 2024
Acquisition, Prestige, Growth

Celebration, FL, April 25, 2024 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a holding company for five agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today announced that it has completed an acquisition transaction and now holds a 51% interest in the Company’s franchisee - La Rosa Realty Lakeland LLC (DBA La Rosa Realty Prestige) (“Prestige”), located in Lakeland, Florida with a separate branch in Winter Haven, Florida.

Key Points: 
  • Prestige generated revenue of $4.7 million and had positive net income in 2023.
  • The franchisee provides residential and commercial real estate brokerage services.
  • Joe La Rosa, CEO of the Company, commented, “With 162 agents, Prestige has solidified its position as number two for agent count and number three for real estate sales in Polk County, Florida in 2023.
  • We believe that these advantages will further strengthen our competitive position in the market and fuel our journey towards sustainable growth.

La Rosa Regains Compliance with Nasdaq

Retrieved on: 
Friday, April 19, 2024
Growth

Celebration, FL, April 19, 2024 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a holding company for five agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today announced that on April 18, 2024, it received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with Nasdaq Continue Listing Rules by satisfying Nasdaq’s Equity Standard under Listing Rule 5550(b).

Key Points: 
  • Celebration, FL, April 19, 2024 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a holding company for five agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today announced that on April 18, 2024, it received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with Nasdaq Continue Listing Rules by satisfying Nasdaq’s Equity Standard under Listing Rule 5550(b).
  • Joe La Rosa, CEO of the Company, commented, “We are pleased to announce that the Company has regained compliance with Nasdaq's continued listing requirements.
  • We believe that this accomplishment underscores our unwavering commitment to corporate governance and generating lasting value for shareholders.
  • In our view, La Rosa stands out in the real estate industry with our distinctive brokerage model, offering agents the choice between a revenue share model or an annual fee-based model with 100% agent commissions.

La Rosa Reports 91% Year-Over-Year Increase in Revenue to $11.4 Million for the Fourth Quarter of 2023

Retrieved on: 
Wednesday, April 17, 2024
National Association of Realtors, Total, Insurance, Partnership, National Association, IPO, Final Offer, Face, Growth, Real estate

CELEBRATION, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a holding company for five agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today provided a business update and reported financial results for the fiscal year ended December 31, 2023.

Key Points: 
  • Notably, in the fourth quarter alone, we acquired six real estate brokerage franchisees, boasting a combined revenue exceeding $35 million in 2022.
  • As a result, I am pleased to report a 91% year-over-year increase in revenue to $11.4 million for the fourth quarter of 2023 compared to $6.0 million for the fourth quarter of 2022.
  • Total revenue for the year ended December 31, 2023, was $31.8 million compared to $26.2 million for the fiscal year ended December 31, 2022.
  • The increase was driven by $4.6 million of revenue from the six acquisitions completed in the fourth quarter of fiscal year 2023, offset by a 13% decrease in total transaction volume.

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting

Retrieved on: 
Monday, April 15, 2024
FDA, Society, Niemann–Pick disease, EAP, American Academy, Patient, Assistant professor, NDA, MD, Deficit spending, Dell Medical School, Disease, PDUFA, University, NPC, SIMD, Pediatrics, Diagnosis, Assistant, Annual general meeting, Therapy, Neuroscience, Pharmaceutical industry

CELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that new long-term real-world data from the arimoclomol expanded access program (EAP: NCT04316637) for the treatment of Niemann-Pick disease type C (NPC) was featured in an oral presentation during the Society for Inherited Metabolic Disorders (SIMD) 45th Annual Meeting taking place at the Sheraton/Le Meridien Charlotte Hotel Complex in Charlotte, NC, from April 14-17, 2024.

Key Points: 
  • “NPC presents a therapeutic challenge, lacking approved treatment options in the U.S. and invariably leading to progressive loss of independence due to physical and cognitive impairments.
  • Among these 26 adults, mean (standard deviation, SD) age at NPC diagnosis and arimoclomol initiation was 23.7 (9.0) and 28.5 (6.5) years, respectively.
  • Patients continued arimoclomol treatment for a mean of 21 months (range: 12-32) and 69% (18/26) had recorded miglustat use.
  • Dr. Patterson’s talk was entitled “Evaluation of the Long-Term Effect of Arimoclomol in NPC - 48 Months Data from CT-ORZY-NPC-002.”

Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility

Retrieved on: 
Wednesday, April 10, 2024
Investment, Sleep, Security (finance), Niemann–Pick disease, Disease, Patient, Acquisition, NPC, Therapy, Pharmaceutical industry

CELEBRATION, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it has entered into a new credit facility provided by leading biotech investors.

Key Points: 
  • CELEBRATION, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it has entered into a new credit facility provided by leading biotech investors.
  • As part of this transaction, the Company has retired its combined existing debt of approximately $43.1M.
  • Net proceeds from the initial $60M draw, after repayment of the existing debt, original issue discount, and fees and expenses associated with this transaction, are approximately $14.0M.
  • The facility is interest-only throughout the five-year term of the facility, with all outstanding principal due on the maturity date of April 5, 2029, and includes certain customary covenants and obligations.

La Rosa to Present at the LD Micro Invitational XIV on April 9th

Retrieved on: 
Wednesday, April 3, 2024
Sofitel New York Hotel

Celebration, Florida--(Newsfile Corp. - April 3, 2024) - La Rosa Holdings Corp. (NASDAQ: LRHC) ("La Rosa" or the "Company"), a holding company for five agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today announced that it will be presenting at the 14th Annual LD Micro Invitational at the Sofitel New York on April 8th - 9th, 2024.

Key Points: 
  • Celebration, Florida--(Newsfile Corp. - April 3, 2024) - La Rosa Holdings Corp. (NASDAQ: LRHC) ("La Rosa" or the "Company"), a holding company for five agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today announced that it will be presenting at the 14th Annual LD Micro Invitational at the Sofitel New York on April 8th - 9th, 2024.
  • Joe La Rosa, Chief Executive Officer of La Rosa, is scheduled to present on Tuesday, April 9th at 11:30 a.m. Eastern Time.
  • Management will also be available for one-on-one meetings with approved qualified investors throughout the conference.
  • To request a meeting with La Rosa, please contact [email protected] or Dean Summers at [email protected] .

Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Retrieved on: 
Thursday, March 28, 2024
Narcolepsy, Exercise, Somnolence, New Drug Application, Patient, Visual analogue scale, Sale, NDA, G&A, Arimoclomol, Nature, IND, Bank statement, Microsoft Access, Investment, Therapy, Priority review, Corporation, Audit committee, Research, Niemann–Pick disease, Medical science liaison, Sleep disorder, Brain, Trial of the century, Safety, Interim, Food, Sleep, QuickStart, Disease, FY, Acquisition, Emetine, UCD, COL3A1, Celiprolol, Syndrome, FDA, Marketing, Conference call, Conference, EAP, SDX, NPC, Epworth Sleepiness Scale, Idiopathic hypersomnia, Physician, PDUFA, Pharmaceutical industry

CELEBRATION, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023. 

Key Points: 
  • ET
    CELEBRATION, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023.
  • “We made solid progress on our key priorities in 2023,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra.
  • Overview of Q4 2023 and FY 2023 Financial Results:
    Net revenue for Q4 2023 was $13.2 million, compared to prior year Q4 net revenue of $2.2 million.
  • ET, to discuss its corporate and financial results for Q4 and FY 2023.

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Retrieved on: 
Tuesday, March 26, 2024
Brain, Disease, Somnolence, Appetite, Partnership, Headache, Visual analogue scale, Patient, Insomnia, EDS, Anxiety, SDX, Doctor of Philosophy, Epworth Sleepiness Scale, Nausea, Clinical trial, Therapy, Safety, Narcolepsy, ESS, IHSS, Idiopathic hypersomnia, Clouding of consciousness, BFS, Food, Pharmaceutical industry

CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial (NCT05668754) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH). This proof-of-concept study was not powered to demonstrate statistical significance.   The data gathered for several secondary and exploratory endpoints, including the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS) and Sleep Inertia Visual Analog Scale (SIVAS) will inform the Phase 3 study design.

Key Points: 
  • CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial ( NCT05668754 ) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH).
  • The data gathered for several secondary and exploratory endpoints, including the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS) and Sleep Inertia Visual Analog Scale (SIVAS) will inform the Phase 3 study design.
  • The results from the completed Phase 2 trial provide key information for the design of a potentially pivotal Phase 3 trial of KP1077 in patients with IH.
  • The Company plans to request an end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration to seek guidance on the Phase 3 clinical trial design.